title: Checkpoint inhibition in meningiomas.
abstract: Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evidence support a role for immune-based therapeutic strategies in the management of meningiomas, especially high-grade subtypes. Meningiomas frequently originate juxtaposed to venous sinuses, where an anatomic conduit for lymphatic drainage resides. Multiple populations of immune cells have been observed in meningiomas. PD-1/PD-L1 mediated immunosuppression has been implicated in high-grade meningiomas, with association between PD-L1 expression with negative prognostic outcome. These data point to the promise of future combinatorial therapeutic strategies in meningioma.
authors.affiliation: Department of Neurosurgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Wenya Linda
authors.initials: WL
authors.lastname: Bi
authors.affiliation: Department of Neurosurgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Winona W
authors.initials: WW
authors.lastname: Wu
authors.affiliation: Department of Pathology, Division of Neuropathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Sandro
authors.initials: S
authors.lastname: Santagata
authors.affiliation: Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
authors.affiliation: Department of Neurosurgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Ian F
authors.initials: IF
authors.lastname: Dunn
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000276:immunology / Q000628:therapy*; D003131:Combined Modality Therapy; D061025:Costimulatory and Inhibitory T-Cell Receptors / Q000037:antagonists & inhibitors; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008579:Meningioma / Q000276:immunology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D061025:Costimulatory and Inhibitory T-Cell Receptors
keywords: PD-1; PD-L1; checkpoint inhibition; immunotherapy; meningioma; targeted pharmacotherapy